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Case Age Sex Mobilization regimen Prior therapy ES Response after ASCT
Observation period
(months) Outcome
1 36 F CY+ GeCSF e No Yes 82 Alive
2 49 F CY+ GeCSF e Yes Yes 81 Alive
3 45 F CY+ GeCSF Dex Yes Yes 45 Alive
4 63 M CY+ GeCSF e Yes No 6 Dead
5 52 M CY+ GeCSF LePAM+PSL Yes No 7 Dead
6 66 F CY+ GeCSF Len No Yes 25 Alive
7 54 M CY+ GeCSF Len+Dex No Yes 20 Alive
Abstracts / Biol Blood Marrow Transplant 19 (2013) S233eS256 S241Conclusion: Lenalidomide has the advantage of being asso-
ciated with a much lower risk of peripheral neuropathy than
new agents such as bortezomib and thalidomide. In addition,
lenalidomide could result in successful ASCT without severe
ES through possible immunomodulating effects before ASCT.
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Fanconi anemia (FA) is an inherited bone marrow failure
syndrome that is associated with multiple congenital
anomalies and a predisposition to cancer, primarily acute
myeloid leukemia and oropharyngeal cancers. Acute
lymphoblastic leukemia (ALL) has also rarely been reported.
Because of their rarity, there is no consensus on how to treat
leukemias when they develop. We report an 8-year old boy
with FA, who developed high-risk pre-B ALL due to an
unfavorable DNA-index, and monosomy 7. Patient received
low-risk ALL induction chemotherapy (vincristine 1.5 mg/m2
iv, weekly  4; prednisone 40 mg/m2/day orally for 28-days
then tapered; Peg-asparaginase 2500 IU/m2 on day 3, intra-
thecal cytarabine on day 0, intrathecal methotrexate on day
14). Patient went in remission promptly by day 14. The
patient developed liver dysfunction and a fungal infection,
which were treated accordingly. Following induction, the
patient developed prolonged myelosuppression that
required regular platelet and PRBC transfusions. He was
treated with non-myelosuppressive post-induction chemo-
therapy for 6 months prior to stem cell transplantation (SCT).
His therapy consisted of two doses of Peg-asparaginase and
two courses of oral dexamethasone for 5 days each. During
this period, serial bone marrow biopsies showed that the
patient remained in remission. Moreover, cytogenetic anal-
ysis showed a disappearance of monosomy 7. Because the
patient had no matched donor, he was given T-cell depleted
haploidentical SCT from his mother. The patient's lymphoid
and myeloid donor cell chimerism was 100 % on day +47 of
SCT. The patient's condition was complicated by a severe
adenovirus infection to which he succumbed on day +60 post
SCT. In conclusion, there is no standard chemotherapy
treatment for patients with FA and ALL. Our patient's high-
risk ALL appeared to respond to low-risk induction and
minimal non-myelosuppressive post-induction chemo-
therapy. These observations suggest that minimal chemo-
therapymay be effective in these patientswhile awaiting SCT.258
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The lifelong health care cost of a patient with sickle cell
disease (SCD) is estimated at w$1 million (Kauf, AJH 2009).
Allogeneic stem cell transplantation (alloSCT) remains the
only curative option for SCD, but no data exists investigating
health care utilization related to alloSCT. We hypothesize
that alloSCT in children with SCD reduces health care utili-
zation in comparison to children with SCD who do not
receive alloSCT.
Financial data from 2002-2011 was analyzed across the
two groups. The health care utilization was determined
over three time periods: pre-alloSCT, during alloSCT (day
0 to day +365), and post-alloSCT. The control group con-
sisted of patients referred for alloSCT and/or HLA typed
without alloSCT. Subjects without inpatient or outpatient
visits during the study time periods were included in the
analysis with a value of 0. The number of inpatient/
outpatient visits was compared with Poisson regression
method, and health care cost was compared with un-paired
t-test.
The alloSCT and control cohorts included 26 patients
(mean age - 6.78yrs), and 47 patients (mean age - 5.15yrs),
respectively. The 3-yr EFS for patients receiving HLA
matched sibling alloSCT was 100% and 44.4% for unrelated
cord blood transplant recipients. The mean total cost per
patient during the alloSCT year was $414,000 inpatient and
$28,000 outpatient. The average monthly inpatient visits
were similar in pre and post-alloSCT time periods; while the
number of inpatient visits in the post-alloSCT period was
signiﬁcantly lower than the control group (0.03 0.10 vs.
0.130.13/month, P ¼ .0003). The average number of
outpatient visits was also signiﬁcantly lower post-alloSCT
compared to pre-alloSCT (1.081.05 vs. 3.844.33/month, P
< .0001). When compared to controls, the post-alloSCT
cohort had signiﬁcantly higher outpatient visits (1.08 1.05
vs. 0.260.29/month, P < .0001). Detailed health care utili-
zation is described in the table below.
This analysis indicates that post-alloSCT health care
utilization decreases when compared to pre-alloSCT.
However, this does not translate into decreased cost when
compared to controls. This may reﬂect the limitation of the
study period to identify the actual changes in utilization over
time. More detailed analysis is ongoing to determine vari-
ables contributing to the substantial alloSCT associated costs
and the long term change in costs over time.
